Are u/loved one diagnosed with #ALKPositive #LungCancer in #India? Join our 🇮🇳 ALK ve Lung Cancer #patients & #caregivers community. Email 'alkpositiveindia2017@gmail.com' with WhatsApp, name, city & proof of ALK ve status to join. You’re not alone💙 @R2SurviveCancer @urvashi01

Happy Heavenly Birthday to Kusum 🎂✨, co-founder of our ALK Positive India support group. Your vision & dedication continue to inspire hope and support for ALK NSCLC patients and caregivers. Forever remembered. ❤️🙏

A patient needs a life-saving medicine. The licence to import it in India for personal use is FREE. Yet many families end up paying agents and losing valuable time to get medicines even during widely used patient assitance program, simply because they don't know the process. To help patients and caregivers, I created a free step-by-step tutorial explaining how to obtain the import licence yourself. Considering the number of queries I continue to receive, this remains a challenge for many patients and families. Unfortunately, some are still being charged unnecessary fees for a process that is free. Hence, sharing this resource again. Link in comments below 👇 ⚠️ Note: The tutorial reflects the process currently followed to obtain an import licence for personal use. As with any regulatory process, requirements may evolve over time, so please verify the latest guidance from the relevant authorities when applying. #ImportLicense #PatientsAssitance #PatientAdvocacy #AccessToMedicines

Live from ASCO: ALKtALK with Dr. Christine Lovly Get real-time updates from the ASCO Annual Meeting and what they mean for the ALK community—straight from a leading researcher and advocate. 📅 May 31, 2026 🕖 7 PM ET 📍 Zoom (broadcast live from ASCO)

the 55% progression-free at 7 years is real and it's a big deal in lung cancer. worth keeping straight though: CROWN is ALK-positive NSCLC only. that's about 4% of lung cancer, selected on one specific gene rearrangement. and the comparator was crizotinib, which is itself a targeted ALK drug, not chemo. so this is a newer targeted drug beating an older targeted drug in a biomarker-picked group. lorlatinib works this well because the patients were selected for the exact thing it blocks. that's the precision-medicine bet paying off, not a result that carries over to metastatic solid tumors in general.

Very important study and data - Young, Never-smokers and Lung Cancer

Important data on young-onset #NSCLC from #ASCO26 👀🫁 Patients <50 years were: 🔹 More likely never-smokers 🔹 More likely metastatic at diagnosis (~70%) 🔹 Enriched for actionable drivers — especially ALK & EGFR 🔹 Had longer OS despite advanced presentation Strong reminder to maintain suspicion for lung cancer in younger patients and prioritize comprehensive molecular testing. Congrats to @TejaVoruganti a fantastic fellow and team 👏 #LungCancer #NSCLC #ThoracicOncology @EGFRResisters @YoungLungCancer @ASCOTECAG

#ASCO26 | Wait or Treat? Brain RT in EGFR/ALK NSCLC Presented by Dr Anil Ramakant Tibdewal. A landmark Phase III randomized trial from @TataMemorial addressed a long-standing question: should asymptomatic brain metastases in oncogene-driven NSCLC receive upfront cranial RT or can radiation safely be deferred? 🧠 Upfront RT significantly improved intracranial control:
▪️ 2-year intracranial progression: 21.7% vs 50.1%
▪️ HR 0.35, p<0.001 @Jani_Chinmay

Excellent presentation by LUNGevity SAB member @JessicaJLinMD opening a new door for ALK trx. Neladalkib is an investigational ALK inhibitor designed to overcome resistance while maintaining brain activity. Early ALKOVE-1 results show meaningful responses even in heavily pretreated patients, including those with prior lorlatinib and CNS disease, with encouraging activity also seen in treatment-naïve patients. One to watch in the next wave of ALK-targeted therapy. #NSCLC #ALKpositive #lungcancer #ASCO26 @MassGeneralNews

ALKOVE-1 suggests the ALK story may not end after lorlatinib. • G1202R ORR: 68% • CNS activity preserved • Post-lorlatinib ORR: 26% Resistance biology may still be targetable. #ASCO2026 #ALK #NSCLC #ThoracicOncology #MVOnco

🚀 7-year follow-up from the CROWN study continues to redefine expectations for ALK NSCLC. Key updates presented by @TonyMok9 at #ASCO26: 🔹 Lorlatinib achieved a 7-year PFS of 55%, with median PFS now exceeding 7 years (HR 0.19 vs crizotinib). 🧠 CNS control remains remarkable:
• 7-year intracranial progression-free rate of 92%
• No new intracranial progression events observed after ~30 months
@Jani_Chinmay

ALK-positive NSCLC remains one of the most rapidly evolving spaces in thoracic oncology. 🫁 Interesting data from the multicenter retrospective study led by @SWaliany evaluating continuation of next-generation ALK TKIs alongside platinum/pemetrexed chemotherapy after progression. The study suggested potential improvements in PFS/OS and reduced CNS progression, particularly in patients treated upfront with 2G/3G ALK inhibitors. Team ALKItects @PatelOncology #Fellowsforum @benlevylungdoc @Jani_Chinmay

Dr. @JessicaJLinMD at #ASCO26 with an important update from ALKOVE-1: phase 1/2 study of neladalkib (NVL-655) in ALK NSCLC. Included 253 patients previously treated - median 3 prior lines, 95% had prior 2G TKI, 75% with prior lorlatinib.

ALKOVE-1 #ASCO2026 Post-lorlatinib ALK inhibition may still be biologically actionable. Neladalkib demonstrated meaningful activity in heavily pretreated ALK NSCLC — with particularly striking signals in: • G1202R resistance mutations • CNS disease • post-lorlatinib sequencing Sometimes durability matters more than raw ORR in resistant disease biology. A glimpse into the evolving future of ALK sequencing beyond lorlatinib. #LungCancer #NSCLC #ALK #ThoracicOncology #PrecisionOncology #TargetedTherapy #Oncology #MVOnco

🧬 A potential new ALK inhibitor enters the field. At #ASCO26, Dr. Jessica Lin presented updated results from ALKOVE-1, the first-in-human phase 1/2 study of neladalkib, a brain-penetrant, ALK-selective, TRK-sparing TKI in advanced ALK NSCLC. Key findings: 🎯 Meaningful activity after prior ALK TKIs
• ORR 46% in lorlatinib-naïve patients
• ORR 26% even in lorlatinib-experienced patients
• Median DOR not reached in lorlatinib-naïve patients @Jani_Chinmay

ALKOVE-1: Safety and activity of neladalkib, a 4th generation, CNS-penetrant, TRK-sparing, ALK inhibitor. #ASCO26 #LCSM @alk_fusion

I am proud to be co-author for this study with Urvashi ji !! #ResearchSavesLives #LungCancer #ClinicalTrials #India #IASLC #WCLC26

I will be presenting at #WCLC26 in Seoul. My research explores the underrepresentation of Indian patients in global lung cancer clinical trials with implications for policy, research and ultimately access to cutting-edge therapies. Looking forward to the discussion. #IASLC #ClinicalResearch #LungCancerResearch @icmrnine @doctorsoumya @RajivKumar1 @PahleIndia @SewantiLimaye @womenlifthealth @VanitaNoronha @oceanblue11oct @ChandnaHimani

RT @ALKPositiveinc: Our ALK Positive crew is rapt as the ALK lung cancer presentations kick off on this opening day of #ASCO26. Thank you D…

Clinical Trials are Not only about Science. For many families, they are also about Hope. Years ago, on International Clinical Trials Day, my late wife Kusum’s journey with Stage 4 ALK ve Lung Cancer (never smoker) and her experience as she was participating in her 1st clinical trial at that time - was shared on one of India leading news channels. Years later, message remains still relevant: - Research truly Saves Lives....But at same time, Awareness, Access, and Trust determine who benefits from this Research. - Access matters - Patient voices matter. On International Clinical Trials Day, today, perhaps we need to continue asking: How do we ensure more patients in India and LMICs (Low-Middle Income Countries) understand, and have access to research? #ICTD2026 #ResearchSavesLives #LMICs #Access #InternationalClinicalTrialsDay #PatientResearchAdvocacy @cspramesh @credoworkshop @CancerGridIndia @docpriyar @iscrindia @AnantBhan @IASLC @ASCO @OncoAlert @oncodaily @ALKPositiveinc @IndiaAlk

What is the optimal treatment for those with PD-L1 high (PD-L1>50%) and driver mutation positive (especially EGFR/ALK mutations) metastatic NSCLC?